Noble Financial Sticks to Its Buy Rating for Caci International

By Jason Carr

Noble Financial analyst Mark Jordan reiterated a Buy rating on Caci International (NYSE: CACI) today. The company’s shares opened today at $124.05.

According to, Jordan is a 4-star analyst with an average return of 8.5% and a 65.8% success rate. Jordan covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Caci International is Strong Buy and the average price target is $150, representing a 20.9% upside.

In a report issued on November 2, Maxim Group also maintained a Buy rating on the stock with a $159 price target.

Based on Caci International’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.09 billion and quarterly net profit of $42.05 million. In comparison, last year the company earned revenue of $1.07 billion and had a net profit of $36.66 million.

Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CACI International, Inc. operates as holding company, which provides information solutions and services in support of national security missions and government transformation for intelligence, defense, and federal civilian customers. It operates through the following segments: Domestic Operations and International Operations.